Ayala Pharm Financials

Ayala Pharm (ADXS) reported $13K in total revenue for fiscal year 2023. This represents a -98.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Ayala Pharm (ADXS) revenue declined by 98.1% year-over-year, from $692K to $13K in fiscal year 2023.

No, Ayala Pharm (ADXS) reported a net income of -$48.1M in fiscal year 2023, with a net profit margin of -369784.6%.

Ayala Pharm (ADXS) reported diluted earnings per share of $-7.99 for fiscal year 2023. This represents a 39.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ayala Pharm (ADXS) had EBITDA of -$35.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

Ayala Pharm (ADXS) had a gross margin of 0.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.

Ayala Pharm (ADXS) had an operating margin of -278969.2% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.

Ayala Pharm (ADXS) had a net profit margin of -369784.6% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.

Ayala Pharm (ADXS) generated -$29.5M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.

Ayala Pharm (ADXS) had $16.6M in total assets as of fiscal year 2023, including both current and long-term assets.

Ayala Pharm (ADXS) invested $24.1M in research and development during fiscal year 2023.

Ayala Pharm (ADXS) had 12M shares outstanding as of fiscal year 2023.

Ayala Pharm (ADXS) had a current ratio of 0.30 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.

Ayala Pharm (ADXS) had a debt-to-equity ratio of -1.68 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

Ayala Pharm (ADXS) had a return on assets of -290.0% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2023 data, Ayala Pharm (ADXS) had $4.9M in cash against an annual operating cash burn of $29.5M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Ayala Pharm (ADXS) has negative shareholder equity of -$24.4M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Ayala Pharm (ADXS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Ayala Pharm (ADXS) has an earnings quality ratio of 0.61x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.